Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.61 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.60 |
| ▸ | NPY1R | P25929 | 4/20 | 0.57 |
| ▸ | NPY2R | P49146 | 4/20 | 0.57 |
| ▸ | NPY4R | P50391 | 4/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.57 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4139781 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| Trifluoroacetic Acid SCHEMBL29454826 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| Trifluoroacetic Acid SCHEMBL2034151 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL23278082 | 0.97 | NMUR2 (0.64) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL29389211 | 0.97 | NMUR2 (0.64) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL25739 | 0.97 | NMUR2 (0.64) | NMUR2NMUR1F2NPY1RNPY2R | |
| Acetic Acid SCHEMBL2037978 | 0.96 | NMUR2 (0.63) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL28366588 | 0.96 | NMUR2 (0.65) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL30753221 | 0.96 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL23630197 | 0.95 | NMUR2 (0.62) | NMUR2NMUR1F2NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | claimed |
| US-9585931-B2 | Cardiovascular disease treatment and prevention | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-20160213738-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-07-28 | — | — | US | claimed |
| WO-2014160187-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271731-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20140271801-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-09-18 | — | — | US | claimed |
| CN-118043084-A | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2024-05-14 | — | — | CN | disclosed |
| EP-4228657-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | disclosed |
| US-20160158279-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9295647-B2 | Systems and methods for delivery of peptides | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150231253-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| WO-2014160047-A2 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140271938-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271808-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231253-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | GNRHR, TRHR, LHCGR | OPRD1 3379/4885NMUR2 562/4885NMUR1 531/4885 |
| US-20160158279-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | NOS1, NOS2, NOS3 | OPRD1 4147/4885NMUR2 974/4885NMUR1 903/4885 |
| US-20140271938-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | GNRHR, TRHR, LHCGR | OPRD1 3379/4885NMUR2 562/4885NMUR1 531/4885 |
| US-20140271731-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | SSTR5, SSTR3, TRHR | OPRD1 4023/4885NMUR2 1788/4885NMUR1 1502/4885 |
| US-20160213738-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | SSTR5, SSTR3, TRHR | OPRD1 4023/4885NMUR2 1788/4885NMUR1 1502/4885 |
| US-20140271801-A1 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION | LIPG, NOS1, CD47 | OPRD1 4636/4885NMUR2 3342/4885NMUR1 2975/4885 |
| US-20140271808-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES | NOS1, NOS2, NOS3 | OPRD1 4147/4885NMUR2 974/4885NMUR1 903/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | OPRD1 4510/4885NMUR2 4096/4885NMUR1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.